Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
$82.10
$0.80(1.09%)
At close: 4:00 PM EST
$82.10
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$65.94 - $87.89
Previous CloseN/A
Volume821.68K
Average Volume (3M)2.85M
Market Cap
$47.96B
Enterprise Value$46.22B
Total Cash (Recent Filing)$3.84B
Total Debt (Recent Filing)$700.30M
Price to Earnings (P/E)35.0
Beta0.67
Next Earnings
Feb 10, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding580,300,000
10 Day Avg. Volume3,542,960
30 Day Avg. Volume2,851,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)4.43
Price to Sales (P/S)8.13
P/FCF Ratio152.63
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue7.85
Enterprise Value/Gross Profit10.04
Enterprise Value/Ebitda26.53
Forecast
1Y Price Target
$98.19Price Target Upside19.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)2.91
Revenue Forecast (FY)$6.63B
Bulls Say, Bears Say
Bulls Say
Clinical Durability And Real‑world OutcomesLong‑term trial results and favorable real‑world registry data for transcatheter mitral and tricuspid devices strengthen physician confidence and support broader adoption of less invasive heart therapies.
Medicare Coverage ExpansionAnalyst expects Medicare to broaden coverage to include asymptomatic severe aortic stenosis, which would materially increase the addressable patient pool for transcatheter aortic valve procedures.
Product Pipeline And ApprovalsExpected US launches of Sapien M3 and Pascal TR, combined with active pivotal trials for aortic regurgitation devices, could create new commercial revenue streams and expand market reach.
Bears Say
Coverage‑with‑evidence RequirementsPersistence of coverage‑with‑evidence‑development obligations and opposition to removing them could limit reimbursement flexibility and slow procedure adoption at more hospitals.
Regulatory Uncertainty From Advisory ReviewA potential Medicare advisory panel review of hospital volume requirements could introduce policy uncertainty and delay definitive coverage decisions for new TAVR programs.
Trade And Supply‑chain RisksIEEPA tariff disputes and related trade issues could create regulatory and supply‑chain pressures that increase costs or disrupt device availability.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $65.94 and its highest was $87.89 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $47.96B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Feb 10, 2026 which is in 5 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Oct 30, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.074.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.62.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 580,300,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.67 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went down -1.234%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$98.19 (19.60% Upside)
$98.19 (19.60% Upside)
Blogger Sentiment
Bullish
EW Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.01%
12-Months-Change
Fundamentals
Return on Equity
13.59%
Trailing 12-Months
Asset Growth
2.32%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Edwards Lifesciences reported strong quarterly performance with significant sales growth across multiple segments, increased full-year guidance, and positive clinical data presentations. However, there were some concerns about declining gross profit margins and upcoming changes in financial leadership.View all EW earnings summariesEW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
6.47% Transcatheter Mitral and Tricuspid Therapies
18.04% Surgical Structural Heart
EW Stock 12 Month Forecast
Average Price Target
$98.19
▲(19.60% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
24.39% Mutual Funds
0.88% Other Institutional Investors
49.80% Public Companies and
Individual Investors